Assembly Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.94
- Today's High:
- $0.98
- Open Price:
- $0.95
- 52W Low:
- $0.77
- 52W High:
- $2.42
- Prev. Close:
- $0.9362
- Volume:
- 13855
Company Statistics
- Market Cap.:
- $56.29 million
- Book Value:
- 1.352
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-63895000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.46%
- Return on Equity TTM:
- -81.94%
Company Profile
Assembly Biosciences Inc had its IPO on 2010-12-17 under the ticker symbol ASMB.
The company operates in the Healthcare sector and Biotechnology industry. Assembly Biosciences Inc has a staff strength of 70 employees.
Stock update
Shares of Assembly Biosciences Inc opened at $0.95 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.94 - $0.98, and closed at $0.94.
This is a +0.41% increase from the previous day's closing price.
A total volume of 13,855 shares were traded at the close of the day’s session.
In the last one week, shares of Assembly Biosciences Inc have slipped by -4.08%.
Assembly Biosciences Inc's Key Ratios
Assembly Biosciences Inc has a market cap of $56.29 million, indicating a price to book ratio of 0.5573 and a price to sales ratio of 10.1459.
In the last 12-months Assembly Biosciences Inc’s revenue was $0 with a gross profit of $-63895000 and an EBITDA of $-88912000. The EBITDA ratio measures Assembly Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Assembly Biosciences Inc’s operating margin was 0% while its return on assets stood at -45.46% with a return of equity of -81.94%.
In Q1, Assembly Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Assembly Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Assembly Biosciences Inc’s profitability.
Assembly Biosciences Inc stock is trading at a EV to sales ratio of 5.8492 and a EV to EBITDA ratio of 0.5146. Its price to sales ratio in the trailing 12-months stood at 10.1459.
Assembly Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $83.12 million
- Total Liabilities
- $9.97 million
- Operating Cash Flow
- $10.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Assembly Biosciences Inc ended 2024 with $83.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $83.12 million while shareholder equity stood at $70.33 million.
Assembly Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $9.97 million in other current liabilities, 52000.00 in common stock, $-743470000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $43.48 million and cash and short-term investments were $73.02 million. The company’s total short-term debt was $2,546,000 while long-term debt stood at $0.
Assembly Biosciences Inc’s total current assets stands at $79.74 million while long-term investments were $0 and short-term investments were $29.53 million. Its net receivables were $717000.00 compared to accounts payable of $1.22 million and inventory worth $0.
In 2024, Assembly Biosciences Inc's operating cash flow was $10.00 million while its capital expenditure stood at $0.
Comparatively, Assembly Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.94
- 52-Week High
- $2.42
- 52-Week Low
- $0.77
- Analyst Target Price
- $2.5
Assembly Biosciences Inc stock is currently trading at $0.94 per share. It touched a 52-week high of $2.42 and a 52-week low of $2.42. Analysts tracking the stock have a 12-month average target price of $2.5.
Its 50-day moving average was $1.03 and 200-day moving average was $1.17 The short ratio stood at 0.88 indicating a short percent outstanding of 0%.
Around 131.9% of the company’s stock are held by insiders while 2751.9% are held by institutions.
Frequently Asked Questions About Assembly Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company’s next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.